• Explore /
  • Poster
  • / Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study—NCT01692496.

Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study—NCT01692496.

Abstract Poster

Authors

null

Claudia María Valverde

Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain

Claudia María Valverde , Javier Martin Broto , Jose A. Lopez-Martin , Cleofe Romagosa , Maria Pilar Sancho Marquez , Juan Antonio Carrasco , Andres Poveda , Sebastian Bauer , Javier Martinez-Trufero , Josefina Cruz , Peter Reichardt , Pablo Luna Fra , Viktor Gruenwald , Oscar Persiva , Diego Varona Porres , Bernd Kasper

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT01692496

Citation

J Clin Oncol 34, 2016 (suppl; abstr 11039)

DOI

10.1200/JCO.2016.34.15_suppl.11039

Abstract #

11039

Poster Bd #

165

Abstract Disclosures

Similar Posters

First Author: Viktor Gruenwald

First Author: Kohei Shitara

First Author: Ecaterina Elena Dumbrava

Poster

2022 ASCO Annual Meeting

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

First Author: Sujana Movva